Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study.

JAAD Int · 2026 · PMC12615299 · PMID 41244857

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients showed a trend toward better repigmentation response during the progressive stage compared to the stable stage.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.